GSK: gets 'breakthrough therapy' status from FDA
(CercleFinance.com) - GSK announced on Tuesday that the US FDA had granted "breakthrough therapy" designation to a proposed antibody-drug conjugate for a particularly aggressive form of lung cancer.
GSK'227, a targeted therapy, is currently in clinical trials for patients with progressive non-small cell lung cancer whose disease is progressing during or after chemotherapy.
This 'relapsing or progressive' form of bronchial cancer is aggressive and associated with a poor prognosis, which means that there is a significant need for new treatments, GSK says.
The 'breakthrough therapy' designation is used to accelerate the development and regulatory assessment of drugs to treat serious or life-threatening diseases.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
GSK'227, a targeted therapy, is currently in clinical trials for patients with progressive non-small cell lung cancer whose disease is progressing during or after chemotherapy.
This 'relapsing or progressive' form of bronchial cancer is aggressive and associated with a poor prognosis, which means that there is a significant need for new treatments, GSK says.
The 'breakthrough therapy' designation is used to accelerate the development and regulatory assessment of drugs to treat serious or life-threatening diseases.
Copyright (c) 2024 CercleFinance.com. All rights reserved.